Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Mark B. Faries et al.|The Lancet|2024Cited by 729
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Carrie R. Daniel et al.|The Lancet Oncology|2018Cited by 658
A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors.Anthony W. Tolcher, Sergio Santillana, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2022Cited by 49
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Giuseppe Gullo, Karl D. Lewis et al.|Journal of Clinical Oncology|2024Cited by 37
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A. Yap, Lu Gan, Randy F. Sweis et al.|Nature Medicine|2026Cited by 2